Cumulus Neuroscience announced publication of CNS-101 results in Frontiers in Digital Health, demonstrating the NeuLogiQ platform was feasible, well tolerated and usable for unsupervised at-home cognitive and eeg assessment across a 52-week protocol.
According to the company, the study enrolled 119 participants—59 with mild Alzheimer’s disease dementia and 60 age-matched healthy controls—at seven UK clinical sites; participants completed 99.7% of initiated sessions and adherence averaged 77% in the dementia group versus 88.8% in controls.
The platform pairs a self-setup wireless dry-sensor eeg headset that is FDA 510(k)-cleared and UKCA-marked as a Class 1 medical device with tablet-based gamified neurocognitive tests and cloud-based infrastructure, and was developed with input from ten pharmaceutical companies.
The home-based protocol included eeg tasks and measures of cognition, mood, speech and sleep, with standard pen-and-paper assessments used as comparators, and the study was designed to assess feasibility rather than treatment effects.
The company says sustained adherence and positive usability ratings over 52 weeks support using frequent, lower-burden digital biomarkers in Alzheimer’s disease trials.
